Ascendis Pharma A (ASND) Depreciation and Depletion (2017 - 2025)

Ascendis Pharma A has reported Depreciation and Depletion for 9 years, with the latest figure at $5.5 million in Q4 2025.

• Quarterly Depreciation and Depletion rose 17.41% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (up 4.01% YoY) and the FY2025 annual result came in at $20.0 million, up 8.67% from the prior year.
• Depreciation and Depletion improved to $5.5 million in Q4 2025 per ASND's latest filing, from $4.6 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $5.5 million in Q4 2025 and troughed at $4.2 million in Q2 2021.
• A 5-year average of $4.7 million and a median of $4.7 million in 2024 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2021 and 2024: Depreciation and Depletion jumped 97.54% in 2021, then retreated 10.37% in 2024.
• Over 5 years, Depreciation and Depletion stood at $4.8 million in 2021, then dropped by 3.02% to $4.6 million in 2022, then gained by 12.47% to $5.2 million in 2023, then dropped by 10.37% to $4.7 million in 2024, then grew by 17.41% to $5.5 million in 2025.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $5.5 million, $4.6 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.